Profound Olfactory Dysfunction in Myasthenia Gravis

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Leon Sarmiento, Fidias E ^a,b   Bayona, Edgardo A ^c   Bayona Prieto, Jaime ^d   Osman, Allen ^a   Doty, Richard L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c Neuronet   (Colombia)

^d Grupo Cirineo Neurorehabilitacion   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MYASTHENIA GRAVIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OLFACTORY DISCRIMINATION; PATIENT MONITORING; POLYMYOSITIS; SCORING SYSTEM; SENSORY SYSTEM EXAMINATION; SMELLING DISORDER; SNIFFING; UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST;

CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; SMELL;

EID: 84867627508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045544     Document Type: Article

References (62)

1. Pradilla G, Leon FE, Guevara GM, Machado CA, Pardo CA, et al. (1983) Myasthenia gravis in the childhood. Acta Pediat Col 1: 7-14.
2. Drachman DB, (1994) Myasthenia gravis. N Engl J Med 330: 1797-1810.
3. Lindstrom JM, (2000) Acetylcholine receptors and myasthenia. Muscle Nerve 23: 453-477.
4. Richman DP, Agius MA, (1994) Myasthenia gravis: pathogenesis and treatment. Semin Neurol 14: 106-110.
5. Leon F, (1995) Myasthenia gravis beginning during pregnancy, partum or puerperium: a distinct clinical entity. Invest Clin 36: 99-100.
6. Viets HR, (1953) A historical review of myasthenia gravis from 1672 to 1900. J Am Med Assoc 153: 1273-1280.
7. Keesey JC, Tourtellotte WW, Herrmann C Jr, Andrews JM, Lindstrom J, (1978) Acetylcholine-receptor antibody in cerebrospinal fluid. Lancet i: 777.
8. Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA, (1998) Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50: 1806-1813.
9. Whiting PJ, Cooper J, Lindstrom JM, (1987) Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain. J Neuroimmunol 16: 205-213.
10. Keesey JC, (1999) Does myasthenia gravis affect the brain? J Neurol Sci 170: 77-89.
11. Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS, (2001) What have we learned about cognition in myasthenia gravis?: a review of methods and results. Neurosci Biobehav Rev 25: 75-81.
12. Hokkanen E, Toivakka E, (1969) Electroencephalographic findings in myasthenia gravis. 180 EEG recordings of 109 patients Acta Neurol Scand 45: 556-567.
13. Saphier D, Birmanns B, Brenner T, (1993) Electroencephalographic changes in experimental autoimmune myasthenia gravis. J Neurol Sci 114: 200-204.
14. Jech R, Ruzicka E, (1996) Brain stem auditory evoked potentials reflect central nervous system involvement in myasthenia gravis. J Neurol 243: 547-550.
15. Fotiou F, Fountoulakis KN, (2000) Evidence for a central cholinergic deficit in myasthenia gravis. J Neuropsychiatry Clin Neurosci 12: 514-515.
16. Steiner I, Brenner T, Soffer D, Argov Z (1994) Involvement of sites other than the neuromuscular junction in myasthenia gravis. In: Lisak RP, editor. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York: Marcel Dekker. pp. 277-294.
17. Balestra B, Moretti M, Longhi R, Mantegazza R, Clementi F, et al. (2000) Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. J Neuroimmunol 102: 89-97.
18. Vernino S, (2008) Neuronal acetylcholine receptor autoimmunity. Ann N Y Acad Sci 1132: 124-128.
19. Garcia-Osta A, Tsokas P, Pollonini G, Landau EM, Blitzer R, et al. (2006) MuSK expressed in the brain mediates cholinergic responses, synaptic plasticity, and memory formation. J Neurosci 26: 7919-7932.
20. Pestronk A, Drachman DB, (1985) Polymyositis: reduction of acetylcholine receptors in skeletal muscle. Muscle Nerve 8: 233-239.
21. Dalakas MC (1987) Polymyositis and dermatomyositis. Boston: Butterworth.
22. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16-23.
23. Bohan A, Peter JB, Bowman RL, Pearson CM, (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56: 255-286.
24. Devanand DP, Tabert MH, Cuasay K, Manly JJ, Schupf N, et al. (2010) Olfactory identification deficits and MCI in a multi-ethnic elderly community sample. Neurobiol Aging 31: 1593-1600.
25. Doty RL, Shaman P, Dann M, (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32: 489-502.
26. Vollmecke T, Doty RL, (1985) Development of the Picture Identification Test (PIT): A research companion to the University of Pennsylvania Smell Identification Test. Chem Senses 10: 413-414.
27. Velayudhan L, Lovestone S, (2009) Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 29: 387-390.
28. Doty RL, (2012) Olfactory dysfunction in Parkinson disease. Nature Rev Neurol 8: 329-339.
29. Iwasaki Y, Kinoshita M, Ikeda K, Shiojima T, Kurihara T, (1993) Neuropsychological function before and after plasma exchange in myasthenia gravis. J Neurol Sci 114: 223-226.
30. Tucker DM, Roeltgen DP, Wann PD, Wertheimer RI, (1988) Memory dysfunction in myasthenia gravis: Evidence for central cholinergic effects. Neurology 38: 1173-1177.
31. Doty RL, Singh A, Tetrude J, Langston JW, (1992) Lack of olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 32: 97-100.
32. Doty RL, Reyes PF, Gregor T, (1987) Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull 18: 597-600.
33. Doty RL, Deems DA, Stellar S, (1988) Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38: 1237-1244.
34. Doty RL, Perl DP, Steele JC, Chen KM, Pierce JD Jr, et al. (1991) Odor identification deficit of the parkinsonism-dementia complex of Guam: Equivalence to that of Alzheimer's and idiopathic Parkinson's disease. Neurology 41: 77-80.
35. Deems DA, Doty RL, Settle RG, Moore-Gillon V, Shaman P, et al. (1991) Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center. Arch Otolaryngol Head Neck Surg 117: 519-528.
36. Burdach K, Doty RL, (1987) Retronasal flavor perception: Influences of mouth movements, swallowing and spitting. Physiol Behav 41: 353-356.
37. Iseki K, Mezaki T, Kawamoto Y, Tomimoto H, Fukuyama H, et al. (2007) Concurrence of nonmyasthenic symptoms with myasthenia gravis. Neurol Sci 28: 114-115.
38. Jacob A, Clack ER, Emery AE, (1968) Genetic study of sample of 70 patients with myasthenia gravis. J Med Genet 5: 257-261.
39. McKeown D, Doty RL, Perl DP, Frye RE, Sims I, et al. (1996) Olfactory dysfunction in Down's syndrome. J Neurol Neurosurg Psychiat 61: 412-416.
40. Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, et al. (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 133: 1747-254.
41. Arendt T, Bigl V, Walther F, Sonntag M, (1984) Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease. Lancet 1: 173.
42. Nakano I, Hirano A, (1983) Neuron loss in the nucleus basalis of Meynert in parkinsonism-dementia complex of Guam. Ann Neurol 13: 87-91.
43. Rogers JD, Brogan D, Mirra SS, (1985) The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 17: 163-170.
44. Arendt T, Bigl V, Arendt A, Tennstedt A, (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol 61: 101-108.
45. Tagliavini F, Pilleri G, Bouras C, Constantinidis J, (1984) The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci Lett 44: 37-42.
46. Doty RL, (2012) Olfaction in Parkinson's disease and related disorders. Neurobiol Dis 46: 527-552.
47. Alkondon M, Rocha ES, Maelicke A, Albuquerque EX, (1996) Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release. J Pharmacol Exp Ther 278: 1460-1471.
48. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW, (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89: 73-120.
49. Li YR, Matsunami H, (2011) Activation state of the M3 muscarinic acetylcholine receptor modulates mammalian odorant receptor signaling. Sci Signal 4: ra1.
50. Hellier JL, Arevalo NL, Blatner MJ, Dang AK, Clevenger AC, et al. (2010) Olfactory discrimination varies in mice with different levels of alpha7-nicotinic acetylcholine receptor expression. Brain Res 1358: 140-150.
51. Mandairon N, Ferretti CJ, Stack CM, Rubin DB, Cleland TA, et al. (2006) Cholinergic modulation in the olfactory bulb influences spontaneous olfactory discrimination in adult rats. Eur J Neurosci 24: 3234-3244.
52. Doty RL, Bagla R, Kim N, (1999) Physostigmine enhances performance on an odor mixture discrimination test. Physiol Behav 65: 801-804.
53. Mandairon N, Peace ST, Boudadi K, Boxhorn CE, Narla VA, et al. (2011) Compensatory responses to age-related decline in odor quality acuity: cholinergic neuromodulation and olfactory enrichment. Neurobiol Aging 32: 2254-2265.
54. Hawkins BT, Egleton RD, Davis TP, (2005) Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol 289: H212-219.54.
55. Chi F, Wang L, Zheng X, Wu CH, Jong A, et al. (2011) Meningitic Escherichia coli K1 penetration and neutrophil transmigration across the blood-brain barrier are modulated by alpha7 nicotinic receptor. PLoS One 6: e25016.
56. Plomp JJ, Molenaar PC, (1996) Involvement of protein kinases in the upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats. J Physiol 493: 175-186.
57. Tanaka S, Hirano T, Saito T, Wakata N, Oka K, (2007) P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. Biol Pharm Bull 30: 291-296.
58. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, et al. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176-179.
59. Knopf PM, Cserr HF, Nolan SC, Wu TY, Harling-Berg CJ, (1995) Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Neuropathol Appl Neurobiol 21: 175-180.
60. Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, et al. (2012) Myasthenia gravis associated neuromyelitis optica-like disease. An immunological link between the central nervous system and muscle? Arch Neurol 68: 1557-1561.
61. Leon-S FE, Pradilla G, Guevara GM, (1996) Myasthenia gravis and pregnancy. Acta Neurol Col 12: 38-45.
62. Leon-S FE, Cotes De AF, (2001) Chronic myasthenia gravis mimicking muscular dystrophy in Eastern Colombia. Rev Neurol 32: 145-147.